Accolade (NASDAQ:ACCD) Announces Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Accolade (NASDAQ:ACCD) posted its quarterly earnings data on Friday. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.01, Zacks reports. Accolade had a negative net margin of 18.16% and a negative return on equity of 18.43%.

Accolade Stock Down 0.4 %

Shares of ACCD stock opened at $6.83 on Friday. Accolade has a 12 month low of $3.08 and a 12 month high of $15.21. The stock has a market cap of $550.07 million, a P/E ratio of -6.63 and a beta of 2.08. The company has a current ratio of 2.72, a quick ratio of 2.72 and a debt-to-equity ratio of 0.49. The company has a 50 day simple moving average of $3.73 and a two-hundred day simple moving average of $3.84.

Analyst Upgrades and Downgrades

Several research firms recently commented on ACCD. William Blair lowered shares of Accolade from a “strong-buy” rating to a “hold” rating in a research note on Wednesday. Barclays dropped their target price on shares of Accolade from $5.50 to $5.00 and set an “equal weight” rating on the stock in a research note on Wednesday, October 9th. Raymond James reiterated a “market perform” rating on shares of Accolade in a research note on Thursday. Leerink Partners reiterated a “market perform” rating on shares of Accolade in a research note on Wednesday. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Accolade in a research note on Wednesday. Ten investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $7.55.

Insider Buying and Selling at Accolade

In related news, CEO Rajeev Singh sold 13,357 shares of the company’s stock in a transaction on Tuesday, December 3rd. The shares were sold at an average price of $3.60, for a total transaction of $48,085.20. Following the completion of the transaction, the chief executive officer now owns 814,316 shares in the company, valued at approximately $2,931,537.60. This represents a 1.61 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last ninety days, insiders sold 40,881 shares of company stock valued at $144,987. Insiders own 8.20% of the company’s stock.

Accolade Company Profile

Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based intelligent technology and multimodal support from a team of advocates and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women’s health specialists, case management specialists, expert medical opinion providers, and primary care physicians.